Stock Analiz

Champions Oncology, Inc. CSBR

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$4.71Market cap $65M
Open the interactive analysis →

Champions Oncology, Inc. (CSBR) is a healthcare company listed in the US with a market value of about $65M. In the twelve months to July 31, 2026 it had revenue of $61M and net income of -$1M, a net margin of -1.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 8% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 58% below the current price.

About Champions Oncology

Champions Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $9M in 2015 to $59M in 2026, growth of about 18.9% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 2% over three years (dilution for shareholders). It spends 15% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.1
P/B16.8
EV/EBITDA226.3
PEG—
Dividend yield0.00%
FCF yield-9.4%
Shareholder yield0.0%
Intrinsic value vs. price−58%

Growth and quality

Revenue growth (1 yr)4.4%
Revenue growth (5 yrs, per year)7.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-3.4%
ROIC (5-yr avg.)-27.0%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$61M$59M$57M$50M$54M$49M$41M$32M$27M$20M$15M
Net income-$1M-$1M$5M-$7M-$5M$548000$362000-$2M$128000-$1M-$7M
Free cash flow-$6M-$5M$7M-$7M$1M$4M-$5M$685000$1M-$2M-$4M
EPS (diluted)$-0.08$-0.08$0.33$-0.54$-0.39$0.04$0.02$-0.18$0.01$-0.13$-0.64
Net margin-1.8%-2.0%8.3%-14.5%-9.9%1.1%0.9%-6.5%0.5%-7.3%-44.7%
ROIC—-10.7%36.4%-132.5%-31.4%3.1%1.8%-17.3%2.4%-35655.3%-1344.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Champions Oncology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 58% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Champions Oncology pay a dividend?

Not currently.

Is Champions Oncology a good stock to buy?

We do not give buy or sell advice. Champions Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.